Welcome to our dedicated page for Sellas Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on Sellas Life Sciences Group stock.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer, with a strong emphasis on acute myeloid leukemia (AML) and other hematologic malignancies. This news page aggregates company announcements, clinical updates, financial disclosures, and collaboration news related to SLS.
Readers can follow developments around SELLAS’ lead product candidate galinpepimut-S (GPS), a WT1-targeted peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center, which is being evaluated in the pivotal Phase 3 REGAL trial as a potential maintenance therapy in AML after second complete remission. News items include updates on the REGAL trial’s progress, Independent Data Monitoring Committee recommendations, and commentary from investigators and key opinion leaders.
The SLS news feed also covers SLS009 (tambiciclib), SELLAS’ highly selective CDK9 inhibitor. Articles highlight Phase 2 clinical data in relapsed or refractory AML with myelodysplastic syndrome-related changes (AML-MR) after prior venetoclax-based treatment, including reported response rates, survival outcomes, and safety findings for SLS009 in combination with azacitidine and venetoclax. Preclinical results in T-cell prolymphocytic leukemia (T-PLL) and mechanistic studies in AML cell lines are also featured in conference-related releases.
In addition to clinical and scientific news, this page includes corporate updates such as participation in investor conferences, warrant exercise transactions, and quarterly financial results as reported in press releases referenced by Form 8-K filings. Investors and followers of SLS can use this page to review the sequence of material events, from R&D days and conference presentations to financing activities and operational updates, in one organized stream of company-specific news.
SELLAS Life Sciences Group (NASDAQ: SLS) announces promising results from a preclinical study of its CDK9 inhibitor, GFH009, targeting neuroendocrine prostate cancer (NEPC). The study showed significant anti-tumor effects, with some samples showing complete inhibition of cancer cell growth at nanomolar concentrations. NEPC, often arising from advanced prostate cancer treatment, has a median survival of only 5.4 months. The findings suggest GFH009 could be a potential treatment option, marking a critical advance in addressing this aggressive cancer variant.
SELLAS Life Sciences Group has appointed Katherine Bach Kalin to its Board of Directors, bringing decades of experience in the life sciences and healthcare sectors. Kalin's extensive background includes leadership roles in strategy, business development, and sales at renowned companies like Celgene and Johnson & Johnson. With her expertise, SELLAS aims to advance its clinical programs, including galinpepimut-S (GPS) and GFH009, which target various cancer indications. This leadership change signifies a strategic move for SELLAS as it prepares for commercialization.
SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $8.4 million for Q2 2022, increasing from $4.6 million in Q2 2021. The company, focusing on cancer therapies, achieved milestones in its lead asset, Galinpepimut-S (GPS), with encouraging clinical results in trials combining GPS with KEYTRUDA and OPDIVO. The GFH009 program also showed promising results with no dose-limiting toxicities. As of June 30, 2022, SELLAS had cash reserves of $27 million, and plans to host a virtual investor symposium on September 15, 2022, to discuss GPS's potential.
SELLAS Life Sciences Group (NASDAQ: SLS) announced promising preclinical results for its CDK9 inhibitor, GFH009, showing significant anti-tumor effects across selected cancer cell lines. The studies indicated that GFH009 inhibited cancer growth by 90 to 100 percent in three out of four cell lines, including pediatric rhabdomyosarcoma and small cell lung cancer. Conducted at Translational Drug Development, these findings will guide the clinical development of GFH009. The company aims to leverage this data for future treatment strategies.
SELLAS Life Sciences Group announced an expansion in its ongoing global Phase 1 clinical trial for the CDK9 inhibitor GFH009, focusing on patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia (AML). A new once-a-week dose cohort has been added, starting at 30 mg. Previous cohorts showed no significant toxicities at the 22.5 mg dose. With safety assessments underway for the twice-a-week regimen, the company aims to determine the optimal dosing for the upcoming Phase 2 study, potentially enhancing efficacy in these patient populations.
The press release from SELLAS Life Sciences Group (NASDAQ: SLS) details a clinical update on its Phase 1 trial of GFH009, a selective CDK9 inhibitor, aimed at treating advanced relapsed lymphoma and acute myeloid leukemia (AML). So far, no dose-limiting toxicities have been observed, with AML patients at the 22.5 mg dose showing significant anti-leukemic effects. The 30 mg dose has commenced, and early efficacy indications are positive in both lymphoma and AML groups. The release highlights ongoing safety assessments and responses from previous cohorts.
SELLAS Life Sciences Group reported promising clinical trial results for galinpepimut-S (GPS) combined with nivolumab in treating malignant pleural mesothelioma (MPM). Patients receiving this combination therapy exhibited a median overall survival of 45.7 weeks compared to approximately 28 weeks for standard care. The study involved eight patients, with 50% showing advanced Stage IV disease. Safety was consistent with nivolumab alone, noting no severe toxicities. SELLAS aims to further evaluate GPS's immunotherapy efficacy.
SELLAS Life Sciences Group (NASDAQ: SLS), a biopharmaceutical firm, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 11:00 a.m. ET. CEO Angelos Stergiou will lead the presentation at the Lotte New York Palace.
SELLAS focuses on developing novel cancer therapies. Its lead candidate, GPS, targets the WT1 protein in various tumors and could be used alone or with other treatments. Additionally, the company is developing GFH009, a selective CDK9 inhibitor licensed from GenFleet Therapeutics.
SELLAS Life Sciences Group (NASDAQ: SLS) has released top-line results from its Phase 1/2 trial of galinpepimut-S (GPS) in combination with Merck’s KEYTRUDA in patients with platinum-resistant advanced metastatic ovarian cancer. The overall response rate is 7.7%, while the disease control rate is 53.9%, significantly higher than the 37.2% achieved with checkpoint inhibitors alone. Median progression-free survival stands at 12 weeks. The trial included 15 patients, with further data expected by year-end. The safety profile aligns with pembrolizumab alone, and no serious adverse effects were reported.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported its financial results for Q1 2022, highlighting key milestones including the in-licensing of GFH009, a selective CDK9 inhibitor. The company raised $25 million through a public offering, enhancing its cash balance to $14.3 million as of March 31, 2022. Licensing revenue fell to $1 million, down from $5.7 million in Q1 2021. R&D expenses rose to $4.6 million. The net loss increased to $16.7 million, or $1.05 per share, from $2.4 million, or $0.16 per share, year-over-year. Major clinical trials, including the Phase 3 REGAL study for GPS, are ongoing.